Evaluation of the Effects of a Cognitive-Motor Fall Prevention Program on Fall Risk Factors
NCT05625828, Not applicable, Active not recruiting, EZUS-LYON 1
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evaluation of the Effects of a Cognitive-Motor Fall Prevention Program on Fall Risk Factors | ClinicalTrials.gov |
| NCT number | NCT05625828 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 176 participants, actual | ClinicalTrials.gov |
| Lead sponsor | EZUS-LYON 1 | ClinicalTrials.gov |
| Conditions | Accidental Falls, Aging, Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Cognitive-motor Physical Activity, Multifactorial Physical Activity | ClinicalTrials.gov |
| First posted | 2022-11-23 | ClinicalTrials.gov |
| Last updated | 2025-07-29 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change of Trail Making Test part A and B scores at Week 12 after intervention | Week 1 and Week 12 | Participants will be asked to perform the Trail Making Test part A and B (Reitan, 1958) following the instructions of the evaluator. It consist of connecting by making pencil lines 25 encircled numbers randomly arranged on a page in proper order (part A) and 25 encircled numbers and letters in alternating order (part B). A sample page including only 8 circles is made for training just before each 25 circle test page. Measurements will take place one week before the first session (Week 1) and one week after the last session (Week 12). Execution time will be measured in seconds. | ClinicalTrials.gov |
| Primary | Change of Stroop Test Victoria version scores at Week 12 after intervention | Week 1 and Week 12 | Participants will be asked to perform the Stroop Test Victoria version (Bayard, 2011) following the instructions of the evaluator. It consist of three pages each containing 6 lines of 4 items and each page includes an additional line for training. In the page 1 participant has to tell the color of 4 dots printed in color ink in left to right order and line by line ; in the page two 4 neutral words are printed in color ink and participants has to tell the color of the ink in the same order ; in page three 4 color words are printed in color ink and participants has to tell the color of the ink in the same order. Measurements will take place one week before the first session (Week 1) and one week after the last session (Week 12). Execution time in second and errors will be measured. | ClinicalTrials.gov |
| Primary | Change of walking speed at Week 12 after intervention | Week 1 and Week 12 | Participants will perform a 6 meters gait measurement where they have to walk at self pace on a 10 meters corridor and time in second will be measured on 6 meters using photoelectric sensors. The first 2 meters are for reaching the pace and last 2 meters are to stop. Measurements will take place one week before the first session (Week 1) and one week after the last session (Week 12). Spontaneous gait speed will be measured in meters per second. | ClinicalTrials.gov |
| Secondary | Change of Choice Stepping Reaction Time at Week 12 after intervention | Week 1 and Week 12 | Participants will perform a Choice Stepping Reaction Task (Lord SR \& Fitzpatrick, 2001) : Participants stand on a nonslip black platform that contained four rectangular panels, one in the front one in the back and one to the side of each foot (up, down, left and right). A computer generates a stimuli (an arrow) indicating the direction of the target the participant has to step on as fast as possible. Choice Stepping Reaction Time that consist of time between the presentation of stimuli and the foot lift will be measured in second. Measurements will take place one week before the first session (Week 1) and one week after the last session (Week 12). | ClinicalTrials.gov |
| Secondary | Change of 30 second sit to stand test score at Week 12 after intervention | Week 1 and Week 12 | This test is a part of the Senior Fitness Test assessment (Fournier et al., 2012). Participants will perform the 30 second sit to stand test, which consist of repetitively standing up from a chair as fast as possible during 30 seconds. Measurements will take place one week before the first session (Week 1) and one week after the last session (Week 12). Number of repetition will be measured. | ClinicalTrials.gov |
| Secondary | Change of 2 minutes step in place test at Week 12 after intervention | Week 1 and Week 12 | This test is a part of the Senior Fitness Test assessment (Fournier et al., 2012). Participants will perform the 2 minutes step in place test which consist of alternatively lifting the knees to an height given by the evaluator as fast as possible during 2 minutes. Measurements will take place one week before the first session (Week 1) and one week after the last session (Week 12). Number of repetitions (corresponding of each knee lift) will be measured. | ClinicalTrials.gov |
| Secondary | Change of one leg standing position time at Week 12 after intervention | Week 1 and Week 12 | This test is a part of the Senior Fitness Test assessment (Fournier et al., 2012). Participants will be asked to stay on one leg standing position and the maximal time they managed to maintain the position will be measured in seconds. Measurements will take place one week before the first session (Week 1) and one week after the last session (Week 12). | ClinicalTrials.gov |
| Secondary | Change of dual-task walking speed at Week 12 after intervention | Week 1 and Week 12 | Participants will perform a 6 meters gait measurement where they have to walk at self pace on a 10 meters corridor and time in second will be measured on 6 meters using photoelectric sensors. The first 2 meters are for reaching the pace and last 2 meters are to stop. Participants have to walk doing the following cognitive tasks. An arithmetic task : Participants have to continuously substract 7 to a 3 digit number given by the evaluator giving results orally. Percentage of error in the cognitive task will be measured and spontaneous gait speed in meters per second will be measured. Measurements will take place one week before the first session (Week 1) and one week after the last session (Week 12). | ClinicalTrials.gov |
| Secondary | Change in the walking trail making test outcomes at Week 12 after intervention | Week 1 and Week 12 | Participants will perform the "Walking Trail Making Test" (WTMT) Task (Alexander et al., 2005 ; Perrochon et al., 2014) on a 10 meters corridor and time in second will be measured on 6 meters using photoelectric sensors. The first 2 meters are for reaching the pace and last 2 meters are to stop. The WTMT contains three experimental conditions : WTMT-N in which participants have to step on numbers from 1 to 20 in ascending order ; WTMT-A in which participants have to step on the same numbers avoiding numeric distractors ; WTMT-B in which participants have to step alternatively on numbers and letters following ascending order and alphabetic order avoiding numeric and alphabetic distractors. Percentage of error and execution time in seconds will be measured. Measurements will take place one week before the first session (Week 1) and one week after the last session (Week 12) | ClinicalTrials.gov |
| Secondary | Change in fall rate at Week 36 after intervention | From Week 12 to Week 36 | Fall rate will be measured using a 6 month follow up. Participants will be asked to fill in an online weekly report indicates whether they had falls or not during the past week. | ClinicalTrials.gov |
| Secondary | Global cognition score at Week 1 | Week 1 | Participants will be asked to perform the different steps of the Montreal Cognitive Assessment following the instructions of the evaluator. This test evaluates multiple cognitive functions such as executive functions, memory, attention leading to a score between 0 (worse score) and 30 (best score). A score between 0 and 20 indicates a major cognitive impairment, a score between 20 and 25 indicates a mild cognitive impairment and and score superior to 25 indicates normal cognitive functioning. Measurement will take place one week before the first session (Week 1). | ClinicalTrials.gov |
| Secondary | Fall Risk score at Week 1 | Week 1 | Fall Risk will be measured using a 7 items questionnaire (Bongue et al., 2011) leading to a score between 0 (best score) and 12 (worst score). A score between 0 and 3 indicates a low risk of falling, a score between 4 and 7 indicates a moderate risk of falling and a score superior to 7 indicates a high risk of falling. Measurements will take place one week before the first session (Week 1). | ClinicalTrials.gov |
| Secondary | Common physical activity at Week 1 | Week 1 | Using a self-reported questionnaire named "Physical Activity Questionnaire for the Elderly ", participants will be asked to register all the physical activities they had on the past week and the time allowed to each activity (De Souto-Barretto et al., 2011). The amount of physical activity will be measured in Metabolic Equivalent Task per minutes per week. Measurements will take place one week before the first session (Week 1). | ClinicalTrials.gov |
| Secondary | Sedentary behaviors at Week 1 | Week 1 | Using a self-reported questionnaire named "Recent Physical Activity Questionnaire" (Golubic et al., 2014), participants will be asked to register all the sedentary behaviors they have usually each day and the time allowed to each behavior. The amount sedentary behavior will be measured in hour per day. Measurements will take place one week before the first session (Week 1). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 7
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)